+221.7%
V vs MRNA
+840.0%
-618.3%
-36.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.3% | -3.9% | +1.7% | -2.2% |
| 7D | -1.5% | -17.6% | +16.1% | -1.1% |
| 30D | +3.7% | -5.1% | +8.9% | +3.7% |
| 3M | +16.4% | +220.8% | -204.5% | +11.7% |
| 6M | +28.4% | +321.7% | -293.3% | +21.9% |
| YTD | +19.8% | +601.3% | -581.5% | +11.2% |
| 1Y | +28.9% | +735.2% | -706.3% | +18.9% |
| 3Y | +70.8% | +170.5% | -99.7% | +60.9% |
| 5Y | +111.1% | -14.6% | +125.7% | +100.7% |
| All | +221.7% | +840.0% | -618.3% | +204.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling